Peak Proteins Archives for Biotherapeutics
In recent years, structural biology has become more prevalent in biotherapeutic development playing a pivotal role in elucidating the antibody-antigen complex formation and understanding the effect on structure of introducing amino acid substitutions. By employing techniques such as X-ray [...]
Two Peak/Sygnature scientists, Juli Warwicker and Mark Abbott, have recently co-authored a paper on a new family of anti-thrombotic biotherapeutics. The paper is from the lab of Dr. Yotis Senis, Research Director, INSERM, Strasbourg, France. The Senis lab have [...]
What is Design of Experiments (DoE) and why use it? Design of Experiments (DoE or sometimes DoX) is an umbrella term that has been coined to cover a particular statistical design and evaluation approach to performing experiments. In essence [...]
The first FDA approved recombinant protein therapeutic developed in 1982 was insulin, developed by Genentech/Eli Lilly under the trade name Humulin. E. coli, transformed with recombinant human DNA, was used to express insulin, which was isolated, refolded, and purified. Since [...]
Peak Proteins
Birchwood House,
Larkwood Way,
Macclesfield,
Cheshire, SK10 2XR
Phone us + 44 (0)115 9415401
Email us: info@peakproteins.com
Peak Proteins is a trading name of Sygnature Discovery Limited
